Brokerages expect Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) to post $910.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings. The highest sales estimate is $925.75 million and the lowest is $882.00 million. Jazz Pharmaceuticals reported sales of $751.81 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 21.2%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year sales of $3.59 billion for the current financial year, with estimates ranging from $3.53 billion to $3.70 billion. For the next fiscal year, analysts expect that the business will post sales of $3.75 billion, with estimates ranging from $3.49 billion to $4.21 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.13. The company had revenue of $813.72 million during the quarter, compared to analysts’ expectations of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive return on equity of 22.45%. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.42 EPS.
Shares of NASDAQ JAZZ opened at $148.53 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.06 and a current ratio of 3.39. The company has a market capitalization of $9.26 billion, a PE ratio of -19.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.79. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $189.00. The company’s fifty day moving average price is $157.79 and its 200 day moving average price is $143.38.
In other news, CEO Bruce C. Cozadd sold 10,772 shares of the stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $158.33, for a total transaction of $1,705,530.76. Following the transaction, the chief executive officer now directly owns 346,062 shares in the company, valued at approximately $54,791,996.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 7,260 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $156.63, for a total value of $1,137,133.80. Following the completion of the sale, the chief executive officer now owns 348,502 shares of the company’s stock, valued at approximately $54,585,868.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,330 shares of company stock valued at $3,483,255. Corporate insiders own 4.30% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Private Capital Group LLC grew its stake in shares of Jazz Pharmaceuticals by 1,975.0% during the first quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 158 shares during the last quarter. Lloyd Advisory Services LLC. acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $29,000. Quent Capital LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $31,000. National Bank of Canada FI purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth about $35,000. Finally, Elequin Capital LP purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $42,000. 93.23% of the stock is currently owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile (Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.